Welcome to our dedicated page for Cross Ctry Healthcare SEC filings (Ticker: CCRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cross Country Healthcare, Inc. (CCRN) SEC filings page on Stock Titan provides centralized access to the company’s public filings with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Cross Country Healthcare submits a range of documents that detail its financial condition, governance, and material corporate events.
Investors can use this page to locate current and historical reports such as annual reports on Form 10‑K and quarterly updates on Form 10‑Q, which the company references in its proxy materials and earnings communications. These reports typically include audited or reviewed financial statements, segment information for Nurse and Allied Staffing and Physician Staffing, discussions of Homecare and Education staffing activities, and management’s analysis of operational efficiency, technology investments, and market conditions.
The filings page also surfaces current reports on Form 8‑K, which Cross Country Healthcare uses to disclose significant events. Recent examples include 8‑Ks reporting quarterly financial results furnished under Item 2.02, updates on the Agreement and Plan of Merger with Aya Healthcare and its termination, the automatic extension of the merger agreement end date, the scheduling of the 2025 Annual Meeting of Stockholders, and the CEO transition in which co‑founder and Chairman Kevin C. Clark was appointed President and Chief Executive Officer.
In addition, users can review the company’s definitive proxy statements on Schedule 14A, which describe board composition, director qualifications, executive compensation, and key proposals submitted to stockholders. These documents also summarize strategic priorities such as strengthening the operational foundation, advancing technology capabilities, and addressing workforce needs across healthcare, homecare, and education markets.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the implications of new 10‑K, 10‑Q, 8‑K, and proxy filings. Real-time updates from EDGAR, combined with simplified explanations of complex disclosures, make it easier to track Cross Country Healthcare’s regulatory reporting and governance developments, including items related to potential transactions, capital allocation, and leadership changes.
Cross Country Healthcare (CCRN) set its 2025 Annual Meeting for December 9, 2025 at 12:00 p.m. ET, to be held virtually at www.virtualshareholdermeeting.com/CCRN2025. Stockholders of record as of October 14, 2025 may vote.
The agenda includes three items: elect seven director nominees for one-year terms; ratify Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025; and approve, on a non-binding advisory basis, 2024 executive compensation.
The company notes its proposed merger with Aya Healthcare, Inc. is expected to close in the fourth quarter of 2025; the Annual Meeting will not be held if the merger closes before December 9.
Governance highlights include a seven-member Board with a Lead Independent Director and fully independent Audit, Compensation, and Governance & Nominating Committees. 2024 results cited include revenue above $1.3 billion, Adjusted EBITDA of $49.1 million (3.7% margin), Adjusted EPS of $0.46, strong cash flow of $120.1 million, repurchases of 2.4 million shares for $36.8 million, and no outstanding long-term debt.
On September 25, 2025 Cross Country Healthcare, Inc. announced its Board set the 2025 virtual-only Annual Meeting for December 9, 2025, which is more than 30 days after last year’s meeting. The meeting will only occur if the pending merger with Aya Healthcare, Inc. (the Aya Merger) is not completed beforehand; the company continues to expect the Aya Merger to close in the fourth quarter of 2025. If the merger is completed first, Cross Country will become a wholly owned subsidiary of Aya and the Annual Meeting will not be held. The company set a deadline of October 10, 2025 for stockholder proposals, nominations and Rule 14a-19 universal proxy notices, and said the proxy statement will be made available by or prior to October 30, 2025.
Cross Country Healthcare, Inc. disclosed that under its Merger Agreement with Aya Holdings II Inc., the contractual “End Date” for completing their planned merger was automatically extended from September 3, 2025 to December 3, 2025. All other terms of the Merger Agreement remain unchanged.
The company and Aya have each certified to the U.S. Federal Trade Commission that they have substantially complied with the agency’s “Second Request” for additional information related to the transaction. Subject to customary closing conditions and required regulatory approvals, the merger is now expected to close in the fourth quarter of 2025.
Cross Country Healthcare disclosed that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 1,887,473.57 shares of its common stock, equal to 5.8% of the class. The filing identifies GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser that may own the securities on the parent’s behalf. The reporting parties certify the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing includes a joint filing agreement and an exhibit identifying the subsidiary relationship.
Cross Country Healthcare (CCRN) Q2 2025 10-Q highlights:
- Revenue fell 19.3 % YoY to $274.1 million; six-month revenue declined 21.1 % to $567.5 million as travel-nurse volumes and bill rates continued to normalize.
- Loss from operations narrowed to $5.9 million (vs. $19.2 million loss LY). Net loss improved to $6.7 million or -$0.20 EPS (LY: -$0.47).
- Gross margin slipped 30 bp YoY to 20.4 % as lower pricing offset cost controls; SG&A down 17 % to $50.1 million.
- Operating cash flow was positive at $9.9 million YTD but sharply below $88.4 million LY, reflecting lower earnings and working-capital unwind.
- Balance sheet remains debt-free; cash & equivalents stable at $81.2 million. Equity totals $412.2 million (book value ≈ $12.7/share).
- Aya Healthcare take-private deal progressing: FTC issued a Second Request on 20 Feb 2025; close expected 4Q 2025. CCRN incurred $6.0 million Q2 and $8.0 million YTD in merger-related costs.
- Segments: Nurse & Allied supplied 82 % of revenue, down 23 %. Physician Staffing rose 3 % YoY.
- No share repurchases in Q2; $40.5 million remains authorized.
Key takeaways: While demand headwinds continue to pressure top line, CCRN preserved liquidity, maintained a debt-free balance sheet, and reduced losses. Future value for shareholders now hinges on successful completion of the Aya merger and potential go-private premium.